GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (NAS:TECH) » Definitions » EBIT per Share

TECH (Bio-Techne) EBIT per Share : $1.07 (TTM As of Mar. 2025)


View and export this data going back to 1989. Start your Free Trial

What is Bio-Techne EBIT per Share?

Bio-Techne's EBIT per Share for the three months ended in Mar. 2025 was $0.25. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $1.07.

During the past 12 months, the average EBIT per Share Growth Rate of Bio-Techne was -15.30% per year. During the past 3 years, the average EBIT per Share Growth Rate was 0.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was 13.60% per year. During the past 10 years, the average EBIT per Share Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Bio-Techne's EBIT per Share or its related term are showing as below:

TECH' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -3.3   Med: 18.4   Max: 83.7
Current: 0.3

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Bio-Techne was 83.70% per year. The lowest was -3.30% per year. And the median was 18.40% per year.

TECH's 3-Year EBIT Growth Rate is ranked worse than
60.58% of 1233 companies
in the Biotechnology industry
Industry Median: 8.9 vs TECH: 0.30

Bio-Techne's EBIT for the three months ended in Mar. 2025 was $40 Mil.


Bio-Techne EBIT per Share Historical Data

The historical data trend for Bio-Techne's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne EBIT per Share Chart

Bio-Techne Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.88 1.00 1.91 2.16 1.25

Bio-Techne Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.28 0.26 0.28 0.25

Bio-Techne EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Bio-Techne's EBIT per Share for the fiscal year that ended in Jun. 2024 is calculated as

EBIT per Share(A: Jun. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=201.425/160.774
=1.25

Bio-Techne's EBIT per Share for the quarter that ended in Mar. 2025 is calculated as

EBIT per Share(Q: Mar. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=40.281/158.944
=0.25

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio-Techne  (NAS:TECH) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Bio-Techne EBIT per Share Related Terms

Thank you for viewing the detailed overview of Bio-Techne's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne Business Description

Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Executives
Kim Kelderman officer: Pres. Diagnostics & Genom 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Robert V Baumgartner director 5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416
John L Higgins director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Roeland Nusse director 473 TENNESSEE, PALO ALTO CA 94306
William Geist officer: PRESIDENT, PROTEIN SCIENCES 900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821
Charles R. Kummeth director, officer: Chief Executive Officer 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
Shane Bohnen officer: SVP - General Counsel 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Brenda S. Furlow officer: SVP - General Counsel 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Norman David Eansor officer: SVP Biotech 8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
James Hippel officer: Chief Financial Officer 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Joseph D Keegan director C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089
Julie L Bushman director 185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214
Rupert Vessey director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Alpna Seth director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Randolph C Steer director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413